Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ShortStop-HER2
NCT06876714Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of trastuzumab and pertuzumab in breast cancer (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Recurrence-Free Survival at 10 years and Functional Assessment of Cancer Therapy-Breast Total Score at 12 months. Started Sep 2025; status: recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06876714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876714.